- Home
- MNR vs NRIX Comparison
MNR vs NRIX Comparison
Compare MNR & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNR | NRIX |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MNR | NRIX |
|---|---|---|
| Price | $13.41 | $23.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $18.00 | ★ $30.50 |
| AVG Volume (30 Days) | 243.0K | ★ 1.1M |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | ★ 14.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,175,390,000.00 | $76,987,000.00 |
| Revenue This Year | $34.60 | N/A |
| Revenue Next Year | $2.35 | $48.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 21.22 | ★ 99.31 |
| 52 Week Low | $10.46 | $8.20 |
| 52 Week High | $15.15 | $25.09 |
Technical Indicators
Market Signals| Indicator | MNR | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 57.86 | 56.17 |
| Support Level | $13.18 | $14.63 |
| Resistance Level | $13.82 | $24.98 |
| Average True Range (ATR) | 0.28 | 1.09 |
| MACD | 0.04 | -0.24 |
| Stochastic Oscillator | 61.38 | 37.44 |
Price Performance
Historical ComparisonAbout MNR Mach Natural Resources LP
Mach Natural Resources LP is an independent upstream oil and gas company. The company is focused on the acquisition, development and production of oil, natural gas, and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas and the panhandle of Texas; the San Juan Basin region of New Mexico and Colorado; and the Permian Basin region of West Texas. The company is organized and managed as a single reportable segment, which is the exploration and production of oil, natural gas and NGLs (E&P Segment).
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.